期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 18, 页码 -出版社
MDPI
DOI: 10.3390/ijms21186630
关键词
A beta; tau; immunotherapy; Alzheimer; scFv; 3xTg-AD
资金
- Ministerio de Economia y Empresa (Spain) [SAF2017-89613-R]
- FEDER
- FPU fellowship
- GSM a PIF-UAB fellowship
Alzheimer's disease (AD) is the most common dementia worldwide. According to the amyloid hypothesis, the early accumulation of the A beta-peptide triggers tau phosphorylation, synaptic dysfunction, and eventually neuronal death leading to cognitive impairment, as well as behavioral and psychological symptoms of dementia. ScFv-h3D6 is a single-chain variable fragment that has already shown its ability to diminish the amyloid burden in 5-month-old 3xTg-AD mice. However, tau pathology is not evident at this early stage of the disease in this mouse model. In this study, the effects of scFv-h3D6 on A beta and tau pathologies have been assessed in 22-month-old 3xTg-AD mice. Briefly, 3xTg-AD female mice were treated for 2 weeks with scFv-h3D6 and compared with 3xTg-AD and non-transgenic (NTg) mice treated with PBS. The treatment with scFv-h3D6 was unequivocally effective in reducing the area of A beta staining. Furthermore, a tendency for a reduction in tau levels was also observed after treatment that points to the interplay between A beta and tau pathologies. The pro-inflammatory state observed in the 3xTg-AD mice did not progress after scFv-h3D6 treatment. In addition, the treatment did not alter the levels of apolipoprotein E or apolipoprotein J. Thus, a 2-week treatment with scFv-h3D6 was able to reduce AD-like pathology in elderly 3xTg-AD female mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据